scholarly journals "Step" versus "phase" in the clinical development of biosimilars: the correct noun holds the key to success

Biosimilars ◽  
2016 ◽  
pp. 25
Author(s):  
Reginald Ewesuedo
Keyword(s):  
Clinical Development

COVID-19 must catalyse changes to clinical development

2020 ◽  
Vol 19 (10) ◽  
pp. 653-654
Author(s):  
Rod MacKenzie ◽  
Peter Honig ◽  
Judy Sewards ◽  
Robert Goodwin ◽  
Marie-Pierre Hellio
Keyword(s):  
Clinical Development

Curcumin: New trends in the formulative and clinical development

Planta Medica ◽  
2014 ◽  
Vol 80 (10) ◽  
Author(s):  
P Morazzoni ◽  
A Riva ◽  
M Ronchi ◽  
G Petrangolini ◽  
W Cabri
Keyword(s):  
Clinical Development

Sending out Biased Signals: an Appropriate Proposition for Pain?

2019 ◽  
Vol 32 (2) ◽  
pp. 108-110 ◽  
Author(s):  
E. Besserer-Offroy ◽  
P. Sarret
Keyword(s):  
Side Effects ◽  
Acute Pain ◽  
Gold Standard ◽  
Pain Treatment ◽  
Opioid Analgesics ◽  
Mu Opioid Receptor ◽  
Clinical Development ◽  
Mu Opioid ◽  
Development Stages ◽  
The Past

In the past few years, several biased ligands acting at the mu-opioid receptor were reported in the literature. These agonists are aimed at reducing pain while having fewer side effects than morphine, the gold standard of opioid analgesics. In this mini-review, we describe and discuss the recent advances in mu-biased ligands actually in preclinical and clinical development stages, including the latest U.S. Food and Drug Administration review of oliceridine, a biased mu-agonist for moderate to severe acute pain treatment developed by the company Trevena.

Sign in / Sign up

Export Citation Format

Share Document